Gough SCL, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, et al
When to Startand When Not To According to the package insert, GLP-1 therapy for obesity is indicated for individuals with a BMI 27 with a weight-related condition, or a BMI 30 alone
[12] [13] As a precautionary measure, people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should discuss this with their clinical team before enrolment in any trial involving this drug class
People with diabetes, particularly severe diabetes, tend to lose less weight with GLP-1s than people without diabetes, so microdosing is less likely to be as effective, though their dose should only be increased as they tolerate it. George said that in her professional opinion, microdosing is a potential option for patients with smaller amounts of weight to lose or as a bridge to start, or wean off, regular GLP-1 medications
Headache disorders affect about 50% of the global population, or roughly 4 billion people, as of 2024 estimates
The Takeaway GLP-1 medications are highly effective for managing type 2 diabetes, but they often come with uncomfortable side effects